Larvol Delta - Alentis-Therapeutics-Doses-First-Patient-in-Phase-12-Clinical-Trial-of-ALEC04-in-Head-and-Neck-Squamous-Cell-Carcinoma-HNSCC

ALE.C04 - Alentis Therap

https://www.businesswire.com/news/home/20231116577905/en/Alentis-Therapeutics-Doses-First-Patient-in-Phase-12-Clinical-Trial-of-ALE.C04-in-Head-and-Neck-Squamous-Cell-Carcinoma-HNSCC

Nov 16, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next